A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 55, Issue 3, 1996, Pages 169-176

  Bendix, G ^a   Bjelle, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; METHOTREXATE; MITOPODOZIDE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; FEMALE; HEMATURIA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME;

EID: 0029929327     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.3.169     Document Type: Article

References (56)

1. Fraser T N. Gold treatment in rheumatoid arthritis. Ann Rheum Dis 1945; 4: 71-5.
2. Research Sub-Committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis. Final report of a multicentre controlled trial. Ann Rheum Dis 1961; 20: 315-33.
3. Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973; 16: 353-8.
4. Sigler J W, Bluhm G B, Duncan H, Sharp J T, Ensign D C, McCrum W R. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 1974; 80: 21-6.
5. Ward J R, Williams H J, Egger M J, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1983; 26: 1303-15.
6. Pullar T, Hunter J A, Capell H A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983; 287: 1102-4.
7. Capell H A, Lewis D, Carey J. A three year follow up of patients allocated to placebo, or oral gold or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis 1986; 45: 705-11.
8. Williams H J, Ward J R, Dahl S L, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31: 702-13.
9. Clark P, Tugwell P, Bennett K, Bombardier C. Metaanalysis of injectable gold in rheumatoid arthritis. J Rheumatol 1989; 16: 442-7.
10. Felson D T, Anderson J J, Meenan R F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-25.
11. Wolfe F, Hawley D J, Cathey M A. Measurement of gold treatment effect in clinical practice: Evidence for effectiveness of intramuscular gold therapy. J Rheumatol 1993; 20: 797-802.
12. Cats A. A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions 1976; 6: 355-63.
13. Jessop J D. Gold in the treatment of rheumatoid arthritis - why, when and how? J Rheumatol 1979; 6 (suppl 5): 12-7.
14. Srinivasan R, Miller B L, Paulus H E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum 1979; 22: 105-10.
15. Kean W F, Anastassiades T P. Long term chrysotherapy. Incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979; 22: 495-501.
16. Luukkainen R. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy. Scand J Rheumatol 1980; (suppl 34): 1-56.
17. Pincus T, Callahan L F, Sale W G, Brooks A L, Payne L E, Vaughn W K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
18. Lockie LM, Smith DM. Forty-seven years experience with gold therapy in 1,019 rheumatoid arthritis patients. Semin Arthritis Rheum 1985; 14: 238-46.
19. Mitchell D M, Spitz P W, Young D Y, Bloch D A, McShane D J, Fries J F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-14.
20. Scott D L, Symmons D P M, Coulton B L, Popert A J. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1987; i: 1108-11.
21. Wolfe F, Hawley D J, Cathey M A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
22. Pincus T, Marcum S B, Callahan L F. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
23. Epstein W V. Editorial. Parenteral gold therapy for rheumatoid arthritis: A treatment whose time has gone. J Rheumatol 1989; 16: 1291-4.
24. Epstein W V, Henke C J, Yelin E H, Katz P P. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 1991; 114: 437-44.
25. Editorial. Gold therapy in rheumatoid arthritis. Lancet 1991; 338: 19-20.
26. Harth M. Gold in rheumatoid arthritis: Standard, substitute or sham? J Rheumatol 1993; 20: 771-3.
27. Bendix G, Bjelle A. Outcome of parenteral gold therapy in RA patients: A comparison between two periods using life-table analysis. Br J Rheumatol 1991; 30: 407-12.
28. Ropes M W, Bennett G A, Cobb S, Jacox R, Jessar R A, 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175-6.
29. Pinals R S, Masi A T, Larsen R A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
30. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940; 7: 172-88.
31. Bergquist R. Immunofluorescence. Evaluation of techniques and reagents with special reference to methodological standardization. Thesis. Stockholm: Karolinska Institutet and the National Bacteriological Laboratory, 1974.
32. Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
33. Miller R G. Survival analysis. New York: John Wiley & Sons, 1981; 3-9.
34. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58: 690-700.
35. Bradley JW. Distribution-free statistical tests. London: Prentice-Hall, 1968; 68-86.
36. Merck C, Angervall L, Kindblom L-G, Odėn A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand [A] 1983; 91 (suppl 282): 1-40.
37. Bretza J, Wells I, Novey H S. Association of IgE antibodies to sodium aurothiomalate and adverse reactions to crysotherapy for rheumatoid arthritis. Am J Med 1983; 74: 945-50.
38. Kay E A, Jayson I V. Risk factors that may influence development of side effects of gold sodium thiomalate. Scand J Rheumatol 1987; 16: 241-5.
39. Cervi P L, Wright P, Casey E B. Audit of full blood count monitoring in patients on longterm gold therapy for rheumatoid arthritis. Ir J Med Sci 1992; 161: 73-4.
40. Situnayake R D, Grindulis K A, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177-83.
41. Batlle-Gualda E, Domenech-Climent V. Life table analysis of treatment terminations with gold and penicillamine in rheumatoid arthritis. Br J Rheumatol 1988; 27 (suppl 2): 114-5.
42. Husain Z, Runge L A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole. J Rheumatol 1980; 7: 825-30.
43. Richter J A, Runge L A, Finals R S, Oates R P. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol 1980; 7: 153-9.
44. Sambrook P N, Browne C D, Champion G D, Day R O, Vallance J B, Warwick N. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol 1982; 9: 932-4.
45. Harth M, Davis P, Thompson J M, Menard H, Beaudet F. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Scand J Rheumatol 1987; 16: 177-84.
46. Morand E F, McCloud P I, Littlejohn G O. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-8.
47. Wijnands M J H, van't Hof M A, van Leeuwen M A, van Rijswijk M H, van de Putte L B A, van Riel P L C M. Long-term second-line treatment: A prospective drug survival study. Br J Rheumatol 1992; 31: 253-8.
48. Capell H A, Porter D R, Madhok R, Hunter J A. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis 1993; 52: 423-8.
49. Rothermich N O, Philips V K, Bergen W, Thomas M H. Followup study of chrysotherapy. Arthritis Rheum 1979; 22: 423.
50. Bendix G, Bjelle A. Proresid therapy in rheumatoid arthritis. A comparison with injectable gold using life-table analysis. Scand J Rheumatol 1993; 22: 77-82.
51. O'Grady J G, Portmann B, Williams R. Fulminant hepatic failure. In: Schiff L, Schiff E R, eds. Diseases of the liver, vol 2, 7th edn. Philadelphia: J B Lippincott Company, 1993; 1077-90.
52. Watkins P B, Schade R, Mills A S, Carithers R L Jr, van Thiel D H. Fatal hepatic necrosis associated with parenteral gold therapy. Dig Dis Sci 1988; 33: 1025-9.
53. Fries J F, Williams C A, Ramey D, Bloch D A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306.
54. Thompson P W, Kirwan J R, Barnes C G. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985; 24: 167-75.
55. Wijnands M J, van Riel P L, Gribnau F W, van de Putte L B. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Semin Arthritis Rheum 1990; 19: 337-52.
56. Ward M M, Leigh J P, Fries J F. Progression of functional disability in patients with rheumatoid arthritis. Arch Intern Med 1993; 153: 2229-37.